OncoBeta GmbH
Lichtenbergstr. 8
85748 Garching n. Munich
GERMANY

China Isotope & Radiation Corporation (CIRC) and OncoBeta sign distribution agreement for Tungsten 188/Rhenium-188 generators

FOR IMMEDIATE RELEASE

Tuesday 30th June 2020

Beijing, China and Garching near Munich, Germany, Tuesday 30th June 2020. CIRC and OncoBeta today announced that they have signed an agreement for the distribution of high energy beta particle W/Re-188 generators in China.

The OncoBeta® high energy beta particle Tungsten-188/Rhenium-188 (W/Re-188) Generators can be used for radiolabeling reactions or directly as a high dose liquid radioactive source. Rhenium-188 (Re-188) is a high energy-emitting radioisotope obtained from the W/Re-188 Generator. Re-188 has shown a high efficiency and value for a variety of therapeutic applications in the nuclear medicine, oncology, and interventional radiology/cardiology areas. Its advantageous physical properties, its potential low cost, and with a long-lived parent make this generator an attractive option for clinical use. The high energy of the emission of Re-188 is particularly well suited for the effective penetration in solid tumors as well as skin cancers.

China's radiopharmaceutical market is now growing rapidly in line with the fast expanding clinical research and use of Targeted Radionuclides such as Rhenium-188. To meet the market demands of W/Re-188 Generators in China, OncoBeta will support CIRC as well as selected projects directly.

"We at OncoBeta are extremely pleased to initiate this collaboration with CIRC, which will give us the opportunity to provide high quality 188W / 188Re Generators to research centers in China" said Shannon D. Brown III, CEO and Managing Director of OncoBeta. *"Our generators are characterized for having high activity concentrations and small elution volumes which can be used for radiolabeling or directly as a high dose liquid radioactive source. With the rising demand of Rhenium-188 in China, we expect to see a fast increase in interest for the High energy beta W/Re-188 generators. We look forward to supporting new projects and exciting market developments."*

About CIRC

China Isotope & Radiation Corporation (CIRC) is the holding subsidiary of China National Nuclear Corporation (CNNC) and the largest nuclear enterprise in the aspects of research and development, manufacture, distribution and service of nuclear products in China. CIRC is mainly engaged in research and application of radioisotope and radiation technology, covering radioisotope preparation by nuclear reactor and cyclotron, radiopharmaceuticals, radioactive source, radiation engineering and processing.

Learn more at: www.circ.com.cn

About OncoBeta® GmbH

OncoBeta® GmbH with its headquarters located in Garching near Munich, Germany, is a medical device and radiochemical company, specializing in the development and commercialization of state-of-the-art, innovative radioisotope therapies and products utilizing Rhenium-188. OncoBeta® offers an innovative Skin Cancer Therapy targeting non-melanoma skin cancers and produces Tungsten (High energy beta particle)-188/Rhenium-188 (W/Re-188) Generators for commercial use.

Learn more us at: www.oncobeta.com

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/OncoBeta/
Instagram: https://www.instagram.com/oncobeta_gmbh/

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta®'s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta®'s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.